drugset

drugset / Trial / NCT06444867

A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968

NCT06444867 ↗

Phase 1 Completed 6 enrolled LEO Pharma

NaSingle-groupOpen-labelTreatment

Summary

The main objective of the study is to evaluate the effect on pain of a single, subcutaneous (SC) dose of LEO 158968 in participants with gout flares.

Timeline

Start: 2025-01-07
Primary completion: 2025-09-18
Completion: 2025-09-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LEO 158968	Unknown	—	Subcutaneous

Indications